Cytokinetics, Incorporated (CYTK) shares fell 1.8% to $67.56 as of September 22, 2026, a modest decline from the prior close of $68.78. BestStocks flagged the session as a major change for CYTK. Below, we break down what changed for CYTK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
CYTK fell 1.8% to $67.56
Cytokinetics, Incorporated moved -4.06% intraday from $72.45 to $69.51. Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript: Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript [2026-09-14] Monitor for follow-through at the close.
This summary describes the catalyst and move as first detected on Sep 15, 2026, 2:43 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
What it means for Cytokinetics, Incorporated investors
For Cytokinetics, Incorporated investors, the recent signals add up to a bearish shift. On the constructive side: CYTK moved +3.08% from its $78.94 open to a $81.37 close on 2026-08-06; Cytokinetics, Incorporated (CYTK) moved +2.53% from $79.11 to $81.11 on 2026-07-21. Weighing against that: Material negative event; Negative session, down 1.8%. Wall Street's consensus price target sits at $112.50, implying +66.5% upside from $67.56. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (40/100). With earnings roughly 43 days out, the next report is the most likely near-term test of the move.
CYTK price reaction
CYTK last traded at $67.56, down $1.22 (-1.77%) from the previous close of $68.78. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $67.56 and $79.20, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Cytokinetics, Incorporated (CYTK)
▼Latest catalyst·a bearish counterpoint
The latest catalyst — a flagged risk event — a bearish counterpoint that challenges the prevailing bullish analyst view.
The consensus analyst price target on Cytokinetics, Incorporated (CYTK) is $112.50, 66.5% above the recent $67.56. Over the past 90 days analysts logged 1 upgrade, 9 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CYTK line up.
▲ The bullish case
+Wall Street's consensus price target of $112.50 implies +66.5% upside from $67.56.
+The Street's most bullish target is $140.00 (+107.2%).
+1 analyst upgrade in the past 90 days, most recently UBS to Buy (2026-06-29).
+CYTK moved +3.08% from its $78.94 open to a $81.37 close on 2026-08-06.
+Cytokinetics, Incorporated (CYTK) moved +2.53% from $79.11 to $81.11 on 2026-07-21.
▼ The bearish case
−Material negative event.
−Negative session, down 1.8%.
−Cytokinetics announced inducement grants of stock options to purchase 52,834 shares on September 15, 2026, disclosed via Globe Newswire on September 17.
−Cytokinetics, Incorporated moved -4.06% intraday from $72.45 to $69.51.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Cytokinetics, Incorporated (CYTK) moved -1.40% from $68.52 to $67.56 on 2026-09-21. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The stock reached a new 30-day low on below-average volume.
Cytokinetics announced inducement grants of stock options to purchase 52,834 shares on September 15, 2026, disclosed via Globe Newswire on September 17. The stock declined 2.04% to $68.49 intraday, though volume remained near normal levels at 0.74x expected for this point in the trading session.
Material / Earnings2026-09-08+3.6%
Cytokinetics, Incorporated (CYTK) moved +4.09% from $72.39 to $75.35 on 2026-09-08. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Cytokinetics shares fell 3.50% to $69.57 following a "sell" rating downgrade on MarketBeat, despite the company announcing positive Phase 3 results for aficamten at the European Society of Cardiology Congress. The decline reflects a "sell the news" reaction as investors took profits after prior gains, with the stock experiencing a broader pullback despite favorable late-stage trial data for non-obstructive hypertrophic cardiomyopathy.
Cytokinetics fell 5.84% to $73.35 following a sell-the-news reaction to positive Phase 3 trial results for aficamten in non-obstructive hypertrophic cardiomyopathy announced at the European Society of Cardiology Congress 2026. Despite the clinical win and a raised analyst price target to $81.00 (per Yahoo Finance), the stock experienced profit-taking consolidation intraday.
Material / Earnings2026-08-17+2.3%
Cytokinetics, Incorporated (CYTK) moved +2.90% from $73.73 to $75.87 on 2026-08-17. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move occurred without elevated trading activity.
Material / Earnings2026-08-13-2.9%
Cytokinetics, Incorporated (CYTK) moved -4.36% from $76.80 to $73.45 on 2026-08-13. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The stock reached a new 30-day low on below-average volume (0.7x the 5-day average).
Material / Earnings2026-08-12-1.1%
Cytokinetics, Incorporated (CYTK) moved -0.70% from $76.17 to $75.64 on 2026-08-12, reaching a new 30-day low. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
In-depth CYTK event analyses
Permanent, dated analyses of CYTK's most significant sessions.
Why did Cytokinetics, Incorporated (CYTK) stock move?
CYTK fell 1.8% to $67.56. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did CYTK stock fall?
CYTK lost 1.77% ($1.22) versus the prior close of $68.78, last trading at $67.56 on 0.8× average volume.
When is Cytokinetics, Incorporated's next earnings date?
CYTK's next earnings report is estimated for 2026-11-04 — about 43 days away.
What is the analyst price target for CYTK?
The consensus analyst price target for CYTK is $112.50, about 66.5% above the current $67.56. Over the past 90 days, analysts recorded 1 upgrade, 9 maintains, and 0 downgrades.
How BestStocks tracks CYTK
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared CYTK-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for CYTK, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
